Volume 14, Issue 54 (4-2007)                   RJMS 2007, 14(54): 203-208 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hashemi S, Hagh Azali M, Mirzaii M, Sohrabpour A, Mohammadnejad M. The Efficacy of Two-Week Metronidazole, Amoxicillin-Based Quadruple Therapy for Eradication of Helicobacter Pylori Infection in Iranian Patients. RJMS 2007; 14 (54) :203-208
URL: http://rjms.iums.ac.ir/article-1-717-en.html
Abstract:   (159625 Views)

    Background & Aim: Metronidazole-based quadruple therapy is widely used by physicians as the first line regimen for eradication of helicobacter pylori(H.pylori) in Iran. However, high rate of metronidazole resistance in Iran casts doubt on the efficacy of such regimens in this country. In this respect, this study tries to determine the efficacy of a quadruple therapy based on metronidazole as the first line treatment of H.pylori. Patients & Method: Two hundred fifty-eight patients with peptic ulcer and proven H.pylori infection were included to take a two-week quadruple therapy consisting of metronidazole, bismuth subcitrate, amoxicillin and omeprazole followed by an additional two-week course of omeprazole. Eradication was described as negative 13C-urea breath test(UBT) one month after the completion of the treatment. Results: The patients’ mean age was 45 years and 64.1% of the subjects were female. Seven patients could not complete the treatment course because of intolerable treatment side effects. Eradication rate was 34.9% based on intention-to treat analysis and 35.9% based on protocol analysis. Conclusion: Quadruple therapy based on metronidazole and amoxicillin has limited efficacy in Iran and should not be used for eradication of H.pylori in this country.

Full-Text [PDF 127 kb]   (46138 Downloads)    
Type of Study: Research | Subject: Gastroentrology

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC-SA 4.0 | Razi Journal of Medical Sciences

Designed & Developed by : Yektaweb